Journal: Scientific Reports

Article Title: Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

doi: 10.1038/s41598-019-47868-0

Figure Lengend Snippet: Levamlodipine Besylate restores spatial learning and memory in VaD mice. Eight weeks after rUCCAO operation, Levamlodipine Besylate was administered orally ( p.o .) at 0.1 or 0.5 mg/kg, and Mementine was administered orally ( p.o .) at a dose of 20 mg/kg for eight weeks. The Morris water maze experiment was used to test the spatial learning of these mice. ( a ) The changes in escape latency were probed to find the hidden platform produced during training trials in each group. * f (10,10) = 5.97, # f (10,10) = 3.44, * p < 0.05 verse sham group; # p < 0.05 verse vehicle group. (means ± SEM, n = 10 mice in each group) ( b ). On the fifth day, each mouse was tested in a probe trial by removing the platform from the pool. The platform crossing time were recorded. * f (10,10) = 4.43, * p < 0.05 verse sham grou p . (means ± SEM, n = 10 mice in each group) ( c ). Time spent in target quadrant in the test day (means ± SEM, n = 10 mice in each group) ( d ). Path length of mice during the MWM test. (means ± SEM, n = 10 mice in each group).

Article Snippet: Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Techniques: Produced

Journal: Scientific Reports

Article Title: Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

doi: 10.1038/s41598-019-47868-0

Figure Lengend Snippet: Levamlodipine Besylate can improve the recognition memory impaired in VaD mice. The novel object recognition test (NORT) was used to evaluate recognition memory. The time spent exploring novel object ( a ) and frequency exploring novel object ( b ) were recorded and analyze. * p < 0.05 verse sham group; # p < 0.05 verse vehicle group; ## p < 0.01 verse vehicle group. (means ± SEM, n = 12 mice in each group).

Article Snippet: Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Techniques:

Journal: Scientific Reports

Article Title: Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

doi: 10.1038/s41598-019-47868-0

Figure Lengend Snippet: Levamlodipine Besylate prevents the dephosphorylation of CaMKII in rUCCAO mice. A significant decrease in the intensity of fluorescence for phospho-CaMKII (Thr286) in CA1 pyramidal neurons of the hippocampus. Levamlodipine Besylate (0.1 mg/kg) could restore the decrease in immunostaining for phospho-CaMKII (Thr286). ( a ) Representative images of phospho-CaMKII in hippocampus CA1 region. ( b ) Quantification of phospho-CaMKII in CA1 region.

Article Snippet: Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Techniques: De-Phosphorylation Assay, Fluorescence, Immunostaining

Journal: Scientific Reports

Article Title: Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

doi: 10.1038/s41598-019-47868-0

Figure Lengend Snippet: Effect of Levamlodipine Besylate on brain vascular structure in rUCCAO mice. ( a ) Representative immunochemistry image of brain blood vessels in hippocampus CA1 region. No significant effect on the vascular structure were observed following Levamlodipine Besylate (0.1 mg/kg and 0.5 mg/kg) or mementine (20 mg/kg) treatment. ( b ) Blood pressure of different group of mice.

Article Snippet: Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Techniques:

Journal: Scientific Reports

Article Title: Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

doi: 10.1038/s41598-019-47868-0

Figure Lengend Snippet: Effect of Levamlodipine Besylate on the activation of astrocyte in rUCCAO mice. Levamlodipine Besylate (0.1 mg/kg and 0.5 mg/kg) or mementine (20 mg/kg) treatment has no significant effect on the activation of astrocyte.

Article Snippet: Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Techniques: Activation Assay

Journal: Scientific Reports

Article Title: Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia

doi: 10.1038/s41598-019-47868-0

Figure Lengend Snippet: Effect of Levamlodipine Besylate on microglia activation in rUCCAO mice. Iba-1 expressed in the hippocampus neurons of vehicle group was significantly increased in rUCCAO mice. Levamlodipine Besylate (0.1 mg/kg and 0.5 mg/kg) or mementine (20 mg/kg) treatment did not significantly attenuated rUCCAO-induced microglia activation in the hippocampus.

Article Snippet: Levamlodipine Besylate was supplied by Shi huida Pharmaceutical Group (Shanghai).

Techniques: Activation Assay

Journal: The Journal of Clinical Hypertension

Article Title: Effect of administration of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non‐dipper patients with grade 1 and 2 hypertension

doi: 10.1111/jch.14630

Figure Lengend Snippet: Effect of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine at different timing. Figure 1A: 24 h DBP; Figure : 24 h SBP; Figure 1C: dDBP; Figure : dSBP; Figure : nDBP; Figure . nSBP. Note: *** p < .001 compared with before drug administration; ### p < .001 compared with the morning medication group.

Article Snippet: (1) Treatment regimen: Irbesartan (75 mg, Zhejiang Nordic Pharmaceutical Co., Ltd., H20217083), orally, q.d.75 mg; hydrochlorothiazide (6.25 mg, North China Pharmaceutical Qinhuangdao Co., Ltd., H20033412), q.d.12.5 mg; and levamlodipine (2.5 mg, Huabei Pharmaceutical Co., Ltd., H20143054), q.d.

Techniques:

Journal: The Journal of Clinical Hypertension

Article Title: Effect of administration of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non‐dipper patients with grade 1 and 2 hypertension

doi: 10.1111/jch.14630

Figure Lengend Snippet: Effect of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine administered at different timing on structural indices of the left ventricle in patients with non‐dipper hypertension. Figure 2A: VST; Figure : LVEDD; Figure : LVM; Figure : PWT; Figure : LVMI. Note: *** p < .001 compared with before drug administration; ### p < .001 compared with the morning medication group.

Article Snippet: (1) Treatment regimen: Irbesartan (75 mg, Zhejiang Nordic Pharmaceutical Co., Ltd., H20217083), orally, q.d.75 mg; hydrochlorothiazide (6.25 mg, North China Pharmaceutical Qinhuangdao Co., Ltd., H20033412), q.d.12.5 mg; and levamlodipine (2.5 mg, Huabei Pharmaceutical Co., Ltd., H20143054), q.d.

Techniques:

Journal: The Journal of Clinical Hypertension

Article Title: Effect of administration of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine at different times on the circadian rhythm of blood pressure and the levels of MMPs and TIMPs in non‐dipper patients with grade 1 and 2 hypertension

doi: 10.1111/jch.14630

Figure Lengend Snippet: Effect of low‐dose irbesartan and hydrochlorothiazide combined with levamlodipine at different timing on the indexes of vascular endothelial function in patients with non‐dipper hypertension. Figure 3A: ET‐1; Figure : NO; Figure : eNOS; Figure : FMD. Note: *** p < .001 compared with before drug administration; ### p < .001 compared with the morning medication group.

Article Snippet: (1) Treatment regimen: Irbesartan (75 mg, Zhejiang Nordic Pharmaceutical Co., Ltd., H20217083), orally, q.d.75 mg; hydrochlorothiazide (6.25 mg, North China Pharmaceutical Qinhuangdao Co., Ltd., H20033412), q.d.12.5 mg; and levamlodipine (2.5 mg, Huabei Pharmaceutical Co., Ltd., H20143054), q.d.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Bioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study

doi: 10.1186/s40360-020-00459-6

Figure Lengend Snippet: Pharmacokinetic parameters of levamlodipine test and reference formulations in the fasted group ( n = 24)

Article Snippet: On December 19, 2019, levamlodipine maleate tablets (Conjupri®) produced by CSPC Ouyi pharmaceutical Co., Ltd. was approved by FDA.

Techniques:

Journal: BMC Pharmacology & Toxicology

Article Title: Bioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study

doi: 10.1186/s40360-020-00459-6

Figure Lengend Snippet: Pharmacokinetic parameters of levamlodipine test and reference formulations in the fed group ( n = 24)

Article Snippet: On December 19, 2019, levamlodipine maleate tablets (Conjupri®) produced by CSPC Ouyi pharmaceutical Co., Ltd. was approved by FDA.

Techniques: